Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May 21;13(11):3020.
doi: 10.3390/jcm13113020.

Stereotactic Body Radiotherapy in Recurrent and Oligometastatic Head and Neck Tumours

Jodie L M Tham  1 , Sweet Ping Ng  1 , Richard Khor  1 , Morikatsu Wada  1 , Hui Gan  2 , Alesha A Thai  2 , June Corry  3 , Houda Bahig  4 , Antti A Mäkitie  5 , Sandra Nuyts  6 , Remco De Bree  7 , Primož Strojan  8 , Wai Tong Ng  9 , Avraham Eisbruch  10 , James C H Chow  11 , Alfio Ferlito  12
Affiliations
Review

Stereotactic Body Radiotherapy in Recurrent and Oligometastatic Head and Neck Tumours

Jodie L M Tham et al. J Clin Med. .

Abstract

The treatment of head and neck cancers (HNCs) encompasses a complex paradigm involving a combination of surgery, radiotherapy, and systemic treatment. Locoregional recurrence is a common cause of treatment failure, and few patients are suitable for salvage surgery. Reirradiation with conventional radiation techniques is challenging due to normal tissue tolerance limits and the risk of significant toxicities. Stereotactic body radiotherapy (SBRT) has emerged as a highly conformal modality that offers the potential for cure while limiting the dose to surrounding tissue. There is also growing research that shows that those with oligometastatic disease can benefit from curative intent local ablative therapies such as SBRT. This review will look at published evidence regarding the use of SBRT in locoregional recurrent and oligometastatic HNCs.

Keywords: head and neck cancer; oligometastatic; recurrent; reirradiation; stereotactic body radiotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Similar articles

See all similar articles

References

    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Brockstein B., Haraf D.J., Rademaker A.W., Kies M.S., Stenson K.M., Rosen F., Mittal B.B., Pelzer H., Fung B.B., Witt M.E., et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: A 9-year, 337-patient, multi-institutional experience. Ann. Oncol. 2004;15:1179–1186. doi: 10.1093/annonc/mdh308. - DOI - PubMed
    1. Cooper J.S., Zhang Q., Pajak T.F., Forastiere A.A., Jacobs J., Saxman S.B., Kish J.A., Kim H.E., Cmelak A.J., Rotman M., et al. Long-term follow-up of the RTOG 9501/intergroup phase III trial: Postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 2012;84:1198–1205. doi: 10.1016/j.ijrobp.2012.05.008. - DOI - PMC - PubMed
    1. Lop J., Venegas M.D.P., Pujol A., Sauter B., Vasquez R., Casasayas M., Quer M., Leon X. Causes of long-term mortality in patients with head and neck squamous cell carcinomas. Eur. Arch. Otorhinolaryngol. 2022;279:3657–3664. doi: 10.1007/s00405-021-07211-8. - DOI - PMC - PubMed
    1. Dawson L.A., Anzai Y., Marsh L., Martel M.K., Paulino A., Ship J.A., Eisbruch A. Patterns of local-regional recurrence following parotid-sparing conformal and segmental intensity-modulated radiotherapy for head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 2000;46:1117–1126. doi: 10.1016/s0360-3016(99)00550-7. - DOI - PubMed

LinkOut - more resources